Current and future clinical applications of ctDNA in immuno-oncology
JC Stadler, Y Belloum, B Deitert, M Sementsov… - Cancer Research, 2022 - AACR
Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …
FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature
N Aide, RJ Hicks, C Le Tourneau, S Lheureux… - European journal of …, 2019 - Springer
This paper follows the immunotherapy symposium held during the European Association of
Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune …
Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune …
Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition
Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …
Molecular and functional imaging in cancer-targeted therapy: current applications and future directions
JW Bai, SQ Qiu, GJ Zhang - Signal Transduction and Targeted Therapy, 2023 - nature.com
Targeted anticancer drugs block cancer cell growth by interfering with specific signaling
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …
Biomarkers for clinical benefit of immune checkpoint inhibitor treatment—a review from the melanoma perspective and beyond
K Buder-Bakhaya, JC Hassel - Frontiers in immunology, 2018 - frontiersin.org
Background Immune checkpoint inhibition (ICI) with anti-CTLA-4 and/or anti-PD-1
antibodies is standard treatment for metastatic melanoma. Anti-PD-1 (pembrolizumab …
antibodies is standard treatment for metastatic melanoma. Anti-PD-1 (pembrolizumab …
Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy
Introduction Immunotherapy has improved outcomes for patients with non-small cell lung
cancer (NSCLC), yet durable clinical benefit (DCB) is experienced in only a fraction of …
cancer (NSCLC), yet durable clinical benefit (DCB) is experienced in only a fraction of …
[HTML][HTML] Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction …
H Jiang, X Yu, N Li, M Kong, Z Ma, D Zhou… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors have greatly improved the prognoses of diverse advanced
malignancies, including gastric and gastroesophageal junction (G/GEJ) cancer. However …
malignancies, including gastric and gastroesophageal junction (G/GEJ) cancer. However …
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
L Goldfarb, B Duchemann, K Chouahnia, L Zelek… - EJNMMI research, 2019 - Springer
Background Immunotherapy represents a new therapeutic approach in non-small cell lung
carcinoma (NSCLC) with the potential for prolonged benefits. Because of the systemic …
carcinoma (NSCLC) with the potential for prolonged benefits. Because of the systemic …
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Purpose We aimed to evaluate if imaging biomarkers on FDG PET are associated with
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience
F Eichhorn, LV Klotz, M Kriegsmann, H Bischoff… - Lung Cancer, 2021 - Elsevier
Objectives A phase II trial investigating the therapeutic effect of neoadjuvant programmed
cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to …
cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to …